Semax and selank for anxiety: what the studies actually say

What did @b.louden06 actually say?

The creator claimed that GE2228, a short peptide derived from something called "spattin," blocks the TREK1 potassium channel to make neurons more excitable. According to them, this boosts BDNF and what they called "CRED" (almost certainly CREB, a transcription factor) through the same pathways antidepressants use, but "way faster." They predicted effects like improved motivation and reward sensitivity within days, acknowledged that effects fade after about a week of continuous use, and admitted that no human studies exist. They also flagged that TREK1 exists outside the brain, creating theoretical cardiovascular or peripheral risks.

To their credit, this was one of the more measured peptide videos you'll see on TikTok. They didn't promise a cure, they quantified their uncertainty, and they explicitly said "no human studies exist yet." That framing matters.

Does the science back this up?

The TREK1 mechanism is real and reasonably well-documented in animal models, but the leap to human antidepressant effects is not established. The foundational work here is Heurteaux et al. (2006, Nature Neuroscience), which showed TREK1 knockout mice displayed antidepressant-like and anxiolytic-like behavior across multiple behavioral tests. That paper is legitimate and widely cited. The idea that blocking TREK1 could have antidepressant effects is not fringe science.

GE2228 itself, however, is a different story. The peptide appears in limited preclinical literature, mostly Russian-language research, and its specific pharmacology in humans is essentially unknown. BDNF upregulation following TREK1 inhibition has been proposed as a downstream mechanism (Bhatt et al., 2020, Frontiers in Pharmacology), but this remains mechanistic speculation rather than demonstrated human pharmacology. The CREB pathway connection the creator references is plausible as a downstream effect but has not been directly measured for this compound. Calling these effects "mechanistically sound" is fair as a hypothesis. Treating it as a reliable prediction of human outcomes is not.

What did they get wrong (or right)?

The creator mispronounced or garbled "CREB" as "CRED," which is minor but worth flagging because CREB is a specific transcription factor and the distinction matters in neurochemistry. More importantly, describing GE2228 as derived from "spattin" is unclear at best. The peptide is sometimes described as derived from spadin, a natural peptide fragment of the TREK1 inhibitor PRSS8 (also called prostasin). If that's what they meant, the mechanism is real, but the source name was wrong enough to be confusing and potentially misleading to viewers trying to research further.

What they got right: the acknowledgment that effects fade with continuous use is consistent with receptor adaptation observed in potassium channel research. The warning about peripheral TREK1 expression is scientifically legitimate. TREK1 is expressed in cardiac tissue and the gastrointestinal tract (Decher et al., 2017, Pflügers Archiv), so "theoretical risk" of peripheral effects is an accurate and responsible flag. The disclaimer that this is not addictive but also not something to run constantly is appropriate given the limited safety profile.

What should you actually know?

GE2228 sits in a category of experimental peptides where the mechanistic story sounds compelling and the animal data is promising, but human evidence is essentially zero. "No human studies exist yet" is not a minor caveat. It means we do not know effective dosing, we do not know pharmacokinetics in humans, we do not know what peripheral TREK1 inhibition does chronically, and we have no safety data at all beyond animal models.

The creator's framing that this "seems to perform as a fast acting antidepressant" is a hypothesis extrapolated from mouse knockout studies and anecdotal reports, not a clinical conclusion. People dealing with depression or low motivation should understand that anecdotal reports in peptide communities carry significant bias and no controls. The comparison to antidepressants hitting the same pathways "just way faster" implies a therapeutic equivalency that has not been tested and should not be assumed.

• TREK1 inhibition as an antidepressant strategy has animal-model support (Heurteaux et al., 2006)
• GE2228 specifically has no published human clinical trials as of current literature
• Peripheral TREK1 expression in cardiac and GI tissue is a real safety consideration
• Sourcing, purity, and dosing of this peptide in gray-market supply chains are unverified